PLENARY KEYNOTE SESSIONS

TUESDAY, JUNE 15

IMPLEMENTING PRECISION MEDICINE AT BIG PHARMA

11:45 am PD-1 Antibodies Are Transforming Cancer Treatment as Precision Medicine Informed Mono- or Combination Therapy
Baynes_RoyRoy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development, CMO, Merck Research Laboratories
Precision medicine tools have enabled PD-1 antibody therapy to transform cancer care in a number of major tumor types. They have also provided insights to resistance biology and potential logical choices for combination therapies. Combination therapies with PD-1 antibodies as foundational are beginning to impact many therapeutic choices.

12:05 pm Sponsored Presentation (Opportunity Available)

12:15 Precision Medicine Strategies: The Next Level
Soares_HollyHolly Soares, PhD, Vice President & Head, Precision Medicine, Pfizer, Inc.
Recent advances and impact of precision medicine strategies in drug development will be reviewed. Technology advances using more spatially and cellularly precise high dimensional profiling will be addressed along with a few novel case studies of patient selection and mechanism-of-action biomarkers.

12:35 Keynote Panel Discussion: Implementing Precision Medicine at Big Pharma
Panelists:
Baynes_RoyRoy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development, CMO, Merck Research Laboratories


Soares_HollyHolly Soares, PhD, Vice President & Head, Precision Medicine, Pfizer, Inc.


Somers_ElizabethElizabeth B. Somers, Senior Director, Diagnostic Pathway Lead, Alzheimer's Disease Franchise, Eisai, Inc.


Su_ZhenZhen Su, MD, MBA, Senior Vice President, Head of Global Oncology Franchise, EMD Serono, a business of Merck KGaA, Darmstadt, Germany


WEDNESDAY, JUNE 16

BIG PHARMA RESPONSE TO COVID-19 PANDEMIC

12:10 pm AstraZeneca R&D: Turning Science into Medicine
Pangalos_MeneMene N. Pangalos, PhD, Executive Vice President, Biopharmaceuticals R&D, AstraZeneca


12:30 Sponsored Presentation (Opportunity Available)

12:40 Reimagining Global Health through Artificial Intelligence: The Roadmap to AI Maturity
Aerts_AnnAnn Aerts, MD, Head, Novartis Foundation


1:00 Keynote Panel Discussion: Big Pharma Response to COVID-19 Pandemic
Panelists:

Cihlar_TomasTomas Cihlar, PhD, Vice President, Virology, Gilead


Additional panelists to be announced

Women in Science

4:15 Keynote Panel Discussion: Women in Science
Panelists:
Emilee ConnorsEmilee Connors, PhD, Scientific Director, Medical Affairs, Merck Research Labs


Razelle KurzrockRazelle Kurzrock, MD, Director, Center for Personalized Cancer Therapy, University of California, San Diego


Lauren LeimanLauren Leiman, Executive Director, BloodPAC


Holly SoaresHolly Soares, PhD, Vice President & Head, Precision Medicine, Pfizer, Inc.


Theresa L. WhitesideTheresa L. Whiteside, PhD, Professor, Pathology, Immunology & Otolaryngology, University of Pittsburgh


THURSDAY, JUNE 17

INNOVATION FOR PHARMA R&D PRODUCTIVITY AND EFFICIENCY

12:25 pm Innovation in Drug Discovery
Rees_StephenStephen Rees, Vice President, Discovery Biology, AstraZeneca


12:45 Sponsored Presentation (Opportunity Available)

12:55 Keynote Panel Discussion: Innovation for Pharma R&D Productivity and Efficiency
Panelists:
Ekert_JasonJason Ekert, PhD, Senior Director & Head, Complex In Vitro Models, GlaxoSmithKline


Jackson_MichaelMichael Jackson, PhD, Senior Vice President, Drug Discovery and Development, Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute


Pangalos_MeneMene N. Pangalos, PhD, Executive Vice President, Biopharmaceuticals R&D, AstraZeneca


Emmett SchmidtEmmett Schmidt, MD, PhD, Vice President, External Collaborations, Oncology Early Development, Merck